Effect of natalizumab on oxidative damage biomarkers in relapsing-remitting multiple sclerosis.
BACKGROUND
Natalizumab is a monoclonal antibody used to treat multiple sclerosis. This study sought to determine whether the protective action of natalizumab involved a reduction in oxidative damage.


METHODS
Twenty-two multiple sclerosis patients fulfilling the revised McDonald criteria were assigned to treatment with 300 mg natalizumab intravenously once monthly (infusion every 4 weeks) in accordance with Spanish guidelines. Carbonylated proteins, 8-hydroxy-2'-deoxyguanosine, total glutathione, reduced glutathione, superoxide dismutase, glutathione peroxidase, and myeloperoxidase levels were measured at baseline and after 14 months' treatment, and the antioxidant gap was calculated.


RESULTS
Natalizumab prompted a drop in oxidative-damage biomarker levels, together with a reduction both in myeloperoxidase levels and in the myeloperoxidase/neutrophil granulocyte ratio. Interestingly, natalizumab induced nuclear translocation of Nrf2 and a fall in serum vascular cell adhesion molecule-1 levels.


CONCLUSIONS
These findings suggest that natalizumab has a beneficial effect on oxidative damage found in MS patients.
Department of Biochemistry and Molecular Biology, Faculty of Medicine, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain.
Inmaculada
I
Tasset
Carmen
C
Bahamonde
Eduardo
E
Agüera
Cristina
C
Conde
Antonio H
AH
Cruz
Aleyda
A
Pérez-Herrera
Félix
F
Gascón
Ana I
AI
Giraldo
María C
MC
Ruiz
Rafael
R
Lillo
Fernando
F
Sánchez-López
Isaac
I
Túnez
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use*; D015415:Biomarkers / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy* / Q000378:metabolism; D051267:NF-E2-Related Factor 2 / Q000378:metabolism; D000069442:Natalizumab; D018384:Oxidative Stress / Q000187:drug effects*; D014157:Transcription Factors / Q000378:metabolism
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000975:Antioxidants; D015415:Biomarkers; D051267:NF-E2-Related Factor 2; C495635:NFE2L2 protein, human; D000069442:Natalizumab; D014157:Transcription Factors